InvestorsHub Logo
Followers 7
Posts 97
Boards Moderated 0
Alias Born 05/12/2004

Re: JellyDonut post# 5028

Thursday, 09/24/2015 6:21:04 PM

Thursday, September 24, 2015 6:21:04 PM

Post# of 5675
I have not telephoned the company in years. I believe I emailed Dr. Tate a couple or three years ago. I never got a response. Since I bought most of this between $.07 and $.15, I have not been as diligent as many people on the these boards. Unless there is a run of big volume, it's simply not worth selling and knocking down the price. I also think that most bulletin boards stocks are huge gambles. Once in a while one hits a winner such as this one (has been so far). That said, if there is some new use for cyclodextrins that can be provided by this company at a significant cost advantage, then we will be seen as very undervalued.

I'm interested in anything that might have to do with broadening the revenue stream, including anything related to the peripheral sub-companies that Dr. Tate used to talk about in the videos and which were part of the website. One of the disadvantages of this company is what they described in most of their SEC filings and on the company website ("The majority of our revenues are from five to ten customers who have historically been repeat purchasers. "), simply that a relative few companies comprise a large portion of their revenue stream. So, a broadening of their revenue stream would be nice to hear about.

I'd be interested in their perspective on the competition, although I would take what they say with a grain of salt. In general, I'm taking a passive approach to this, and I'm pleased with the general direction (up). Thanks for asking. I appreciate your enthusiasm, but not everything I'm seeing develop is, at least to me, is viewable as a long-term positive. Hence, my recent post. Good luck to you as well.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYTH News